Elvitegravir
Stribild (fixed-dose combination) | |
Other names | GS-9137 |
---|---|
License data | |
Routes of administration | By mouth |
ATC code | |
Pharmacokinetic data | |
Protein binding | 98% |
Metabolism | liver, via CYP3A |
Elimination half-life | 12.9 (8.7–13.7) hours |
Excretion | liver 93%, renal 7% |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Elvitegravir (EVG) is an
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.[8]
Medical uses
In the United States, elvitegravir can be obtained either as part of the combination pills
Vitekta is
Adverse effects
The most common side effects of taking elvitegravir are
Interactions and contraindications
Elvitegravir is metabolised via the liver enzyme
Furthermore, elvitegravir is a weak to medium inducer of CYP1A2, CYP2C19, CYP2C9, CYP3A, and a number of UGTs; the clinical relevance of these findings is however unclear.[11]
Pharmacology
Mechanism of action
Elvitegravir inhibits the enzyme
Pharmacokinetics
The drug is taken by mouth. When taken together with ritonavir and a meal, it reaches highest blood plasma concentrations after four hours.
References
- ^ "Phase III Clinical Trial of Elvitegravir". Gilead Press Release. 22 July 2008. Archived from the original on 2013-02-08.
- ^ "Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor". Gilead Press Release. March 22, 2008. Archived from the original on 2013-02-08.
- PMID 17977962.
- PMID 17933730.
- S2CID 24183976.
- ^ "FDA Approval Bulletin". Archived from the original on 2014-11-03.
- ^ "Press Announcements - FDA approves new treatment for HIV". www.fda.gov. Retrieved 2016-01-10.
- ^ Thaczuk D, Carter M (19 September 2007). "ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents". Aidsmap.com. Archived from the original on 2010-01-02.
- ^ "FDA Approved Drug Listing". Retrieved March 3, 2017.
- ^ a b "Vitekta Package Insert". Foster City, CA: Gilead Sciences, Inc. 2014. Retrieved November 1, 2014 – via U.S. Food and Drug Administration.
- ^ a b c d e f Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
- S2CID 1964934.
External links
- "Elvitegravir". Drug Information Portal. U.S. National Library of Medicine.